Ocean Nutrition Canada Limited (ONC; Nova Scotia, Canada) announced that Arnold Bread has launched Grains & More Double Omega, a new bread formulated to improve heart health.
Ocean Nutrition Canada Limited (ONC; Nova Scotia, Canada) announced that Arnold Bread has launched Grains & More Double Omega, a new bread formulated to improve heart health.
The Grains & More Double Omega bread serves up 50 mg of the MEG-3® Omega-3 EPA/DHA ingredient made from fish oil per two slices. In addition to including MEG-3® for heart health benefits, each slice also contains 20 grams of whole grains per slice and provides a good source of fiber and protein. This new bread product is available in supermarkets and mass retail locations in Northeast United States under the Arnold® brand name, and under the Brownberry brand name in the Midwest United States.
This bread offers the added value of the MEG-3® ingredient which provides the complete health benefits of Omega-3 EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from fish oil which are essential fatty acids that have been scientifically linked to supporting cardiovascular health, healthy brain function, and overall good health, according to the company.
“We are very excited to be working with Arnold® Bread to provide a bread product that is loaded with Omega-3. If consumers are not eating at least two 4 oz servings of oily fish per week then they are not consuming adequate levels of Omega-3 according to the U.S. Dietary Guidelines. With Double Omega, consumers can get the goodness of fish, while enjoying the great taste of Arnold’s Bread,” said Lori Covert, Vice President of Marketing & Communications at ONC.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.